Abstract: The invention provides devices and methods that can prevent or ameliorate bronchoconstriction. In particular, the invention provides devices and methods in which a signal is delivered to the vagus nerve or the pulmonary branches of the vagus nerves. The signal is able to treat bronchoconstriction and prevent and/or ameliorate bronchoconstriction.

Abstract: Stimulation of neural signalling of an apical splenic nerve can modulate pro- and anti-inflammatory molecules levels, thereby reducing inflammation and providing ways of treating inflammatory disorders.

Abstract: Modulation of neural activity in the superior laryngeal nerve (SLN) or cervical sympathetic trunk (CST) is effective in treating diseases and conditions mediated by thyroid and parathyroid hormones, in particular diseases associated with calcitonin secretion (e.g. osteoporosis) or diseases associated with thyroxine secretion (e.g. hypothyroid syndrome).

Abstract: Modulation, preferably inhibition, of neurosignaling of a cardiac-related sympathetic nerve in the extracardiac intrathoracic neural circuit is effective in stabilizing cardiac electrical and/or mechanical function, thereby providing ways of treating or preventing cardiac dysfunction such as arrhythmias.

Abstract: This disclosure provides an apparatus or system for the modulation of neural activity in the cervical sympathetic chain (CSC) or superior cervical ganglion (SCG) or SCG post-ganglionic branch(es) and for the treatment of sleep apnoea, as well as methods for their use.

Abstract: The present disclosure provides an apparatus or system and methods for treating xerostomia or Sjögren's Syndrome in a subject.

Abstract: The present invention provides devices and methods that can prevent or ameliorate bronchoconstriction by stimulating neural activity, in contrast to those techniques based on denervation, ablation or blocking of neural activity. Methods and devices according to the invention may act responsively or on demand, can preserve neuronal structure and function and will be associated with minimal collateral side-effects. In particular, the invention provides devices and methods in which a signal is delivered to the vagus nerve, for example the cervical vagus nerve or the pulmonary branch of the vagus nerve, in order to stimulate neural activity in the vagal nerve.

Abstract: The present invention provides improved devices, systems and methods to provide for control of bladder function. Aspects of the present disclosure relate to an apparatus, system and/or a method for modulating the neural activity of afferent fibres of the pelvic nerve to bladder function. In one aspect, the disclosure relates to the use of pharmaceutical compositions in patients undergoing neuromodulation therapy.

Abstract: The invention provides devices, apparatuses, systems and methods for treating and ameliorating inflammation of the gut. In particular, the invention provides devices, apparatuses and methods in which a neuromodulatory signal is delivered a splenic nerve and/or superior mesenteric plexus (SMP). The signal is able to treat inflammatory disorders, e.g., colitis, for example in Inflammatory Bowel Disease.

Abstract: The present invention relates to medical devices and, more particularly, to medical devices that deliver neuromodulating therapy.

Abstract: The invention refers to a device for inhibiting the neural activity of a carotid sinus nerve (CSN) or carotid body of a subject, the device comprising: one or more transducers configured to apply a signal to the CSN or associated carotid body of the subject, optionally at least two such transducers; and a controller coupled to the one or more transducers, the controller controlling the signal to be applied by the one or more transducers, such that the signal inhibits the neural activity of the CSN or carotid body to produce a physiological response in the subject, wherein the physiological response is one or more of the group consisting of: an increase in insulin sensitivity in the subject, an increase in glucose tolerance in the subject, a decrease in (fasting) plasma glucose concentration in the subject, a reduction in subcutaneous fat content in the subject, and a reduction in obesity in the subject.